A foreign manufacturer appoints a Malaysian distributor in three moves: verify the basics (the distributor's current licences and GDP compliance - noting that import licences are product-specific, so yours will be added later - plus cold chain status where relevant), match the distributor to the channel the product actually needs (retail pharmacy, hospital and institutional, clinics, or wholesale), and fix the terms that protect you in the distribution agreement - above all, keep the product registration out of the distributor's name. The registration is held by a Marketing Authorisation Holder (MAH); if the same company is both your distributor and your MAH, changing distributors later requires their cooperation. Appoint the distributor for distribution; if the same company is to hold the registration too, fix dossier ownership, transfer cooperation and exit terms in the contract before signing.
A note on terms: NPRA officially calls the holder the Product Registration Holder (PRH). Throughout RHMI's guides we use the equivalent international term, Marketing Authorisation Holder (MAH) - they mean the same party.
If you came back from CPHI or a partner search with a list of Malaysian distributor contacts, our distributor guide covers who the players are. This article is about choosing between them - and what to fix in the agreement before you sign, so the commercial relationship never takes your registration hostage.
First, separate the two decisions
"Choosing a distributor" in Malaysia is usually two decisions disguised as one: who moves and sells the product, and who holds its registration. They do not have to be the same company - and combining them is safe only with the right contract, because the holder controls your market access while the distributor controls your revenue. Make the holder decision first; it changes what you need from the distributor. Who should hold the registration · The three structures compared.
Selection: what to verify before commercial talks
1. Licences - with a nuance
Wholesale runs under a Wholesaler's Licence and import under an Import Licence, both premises-tied and issued to Malaysian-registered companies. The Import Licence is also product-specific and sits with the registration holder or its appointed importer - so at shortlist stage your product's licence does not exist yet. What you verify now: the distributor's current licences, and that their premises meet GDP as a licensing condition (inspections are carried out by NPRA and/or the Pharmacy Enforcement Division).
2. Cold chain, where relevant
For temperature-sensitive products, check whether the facility appears on NPRA's Cold Chain Facilities List - importers and wholesalers found compliant at inspection - and how recent that inspection is; the status reflects the inspection date. How licences, GDP and cold chain work.
3. Channel fit
Malaysian distribution splits into distinct channels - retail pharmacy chains and independents, private hospitals and institutional buyers, clinics, and government supply. A distributor dominant in one channel may barely touch another. Ask where their revenue actually comes from, and match it to where your product sells.
4. Portfolio conflict
A distributor already carrying a competing product will always have a priority conflict. Ask for the product list before discussing terms.
5. Size versus attention
The largest distributors offer reach; a mid-size specialist may offer focus. The practical question is not "who is biggest" but "whose incentive is my product big enough to matter to". Who the players are.
The agreement: terms that decide who controls what
The distribution agreement is where control is won or lost - not in the pitch meetings. Commercial practice varies and your counsel drafts the contract, but a foreign manufacturer should expect these areas to be answered in writing:
| Area | What to settle in writing |
|---|---|
| Registration | The preferred structure keeps the registration out of the distributor's name; if the roles are combined, the contract settles dossier ownership, transfer cooperation and exit terms before signing |
| Territory and channel | Which channels and regions the appointment covers - and which it does not |
| Exclusivity | If exclusive: for which products, for how long, against what minimum purchase or performance commitments |
| Performance | Order volumes or sales targets with a defined review cycle, and what happens when they are missed |
| Term and exit | Duration, notice periods, and what happens to stock, open orders and channel relationships at exit |
| Pharmacovigilance interface | Who receives complaints and adverse event reports first, and how fast they reach the holder - the holder carries the legal duty |
| Shortage cooperation | Since 1 July 2026 the holder must notify NPRA of shortages and discontinuations (at least six months ahead, or as soon as practicable) - the agreement should oblige the distributor to share supply signals early enough to meet that duty |
| Data | Sales and stock reporting: what you see, at what granularity, how often |
The single most expensive clause to get wrong is the first one. Everything else in the table is renegotiable at renewal; a registration sitting in the distributor's name is renegotiable only with their cooperation. The decision checklist for the holder question.
The structure that keeps both sides honest
The setup RHMI operates: an independent holder keeps the registration, and distribution is appointed - and re-appointed - on commercial merit. The distributor competes on service and reach, not on custody of your market access. Distributors confident in their commercial performance rarely object. When holding the registration is made a condition of distribution, you are being asked for more than a distribution deal - price that in. How we hold registrations · Import and distribution.
Frequently asked questions
Should our distributor also hold our product registration?
It is common and it is convenient - and it ties your market access to one commercial relationship. If you do combine the roles, fix dossier ownership, transfer cooperation and exit terms in the contract before signing. The safer structure keeps the holder independent.
Can we appoint more than one distributor in Malaysia?
Yes. Multiple distributors by channel or region are possible, and an independent holder structure makes adding or changing them straightforward - the registration is untouched by the commercial changes.
What licences must a Malaysian distributor show us?
A Wholesaler's Licence, and an Import Licence if they also import - both issued to Malaysian-registered companies with GDP-compliant premises. For temperature-sensitive products, ask whether the facility appears on NPRA's Cold Chain Facilities List, and how recent that inspection is.
How do we exit a distribution agreement without losing the market?
If the registration is held independently, exit is commercial: notice, stock, handover. If the distributor holds the registration and the holder is to change too, exit also requires a change of holder, which the current holder files - which is why the exit terms belong in the contract from day one.
You might also find useful
- Pharmaceutical Distributors in Malaysia: Top Companies and How to Choose
- Distributor as Your MAH in Malaysia: Lock-in Risk and How to Keep Control
- Importing and Distributing Pharmaceuticals in Malaysia: Licences and GDP
- Sources:
- NPRA - Guideline on Application of Manufacturer's, Import and Wholesaler's Licenses for Registered Products, 3rd Edition, March 2025: npra.gov.my
- NPRA - Guideline on Good Distribution Practice, Third Edition, 2018: npra.gov.my
- NPRA Drug Registration Guidance Document (DRGD): npra.gov.my (DRGD)
- NPRA - medicine shortage and discontinuation reporting guidance (in force 1 July 2026): npra.gov.my
- Editorial note: This page is general business and regulatory information for manufacturers evaluating Malaysia. It is not legal advice; distribution agreements should be drafted and reviewed by your counsel. Administrative details change - confirm them against NPRA's current guidance before acting. Last reviewed against NPRA guidance: 4 September 2026.